ISORDIL TITRADOSE Rx
Generic Name and Formulations:
Isosorbide dinitrate 5mg, 40mg; scored oral tabs.
Valeant Pharmaceuticals, Inc
Indications for ISORDIL TITRADOSE:
Prophylaxis of angina. Not for acute attacks.
Initially 5–20mg 2–3 times per day. Maintenance: 10–40mg 2–3 times per day; allow a daily dose-free interval of at least 14hrs.
Concomitant PDEIs (eg, sildenafil, tadalafil, vardenafil), riociguat.
Recent MI. CHF. Hypotension. Volume depletion. Hypertrophic cardiomyopathy. Tolerance may develop. Elderly. Pregnancy (Cat.C). Nursing mothers.
See Contraindications. Severe hypotension with sildenafil. Hypotension potentiated with alcohol, other vasodilators, calcium channel blockers.
Headache, orthostatic hypotension, paradoxical bradycardia.
Sublingual tabs formerly known under the brand names Isordil, Sorbitrate.
Sublingual—contact supplier; Titradose—100
Sign Up for Free e-newsletters
- Study Finds Association Between Folate Intake and Risk of Cutaneous Melanoma
- Qualitative Analysis of Myeloma Patients' Experience Following Hematopoietic Stem Cell Transplant
- Melanoma Outcomes Improved With Nivolumab Alone or Plus Ipilimumab
- Involved-Field Radiotherapy Plus Chemotherapy Prolonged PFS in Follicular Lymphoma
- Patient Fears of Placebo Use in Clinical Trials
- Implementing an Ambulatory Adherence Program May Improve Oral Anticancer Medications Compliance
- Exercise Habits Influence Mortality in Adult Survivors of Childhood Cancer
- Managing Dyspnea With Fentanyl in Patients With Cancer at End of Life
- CALM: A Depression Intervention for Cancer Patients at the End of Life
- High BMI Among Premenopausal Women May Improve Risk for Breast Cancer
- Genetic Link Between Depression and Breast Cancer Remains Unclear
- Bariatric Surgery Reduced Risk of Some Cancers in Obese Patients
- Bleeding Disorder Treatments: Hemophilia A
- Guideline Recommendations Offer No OS Benefit for Younger Patients With Rectal Cancer
- Bleeding Disorder Treatments: von Willebrand Disease
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|